Idiopathic Pulmonary Fibrosis and a Role for Autoimmunity

Overview

Journal Immunol Cell Biol

Publisher Wiley

Specialties Allergy & Immunology
Cell Biology

Date 2017 Mar 31

PMID 28356570

Citations 35

Authors

Gerard F Hoyne

Hannah Elliott

Steven E Mutsaers

Cecilia M Prele

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is typically associated with extensive and progressive fibrosis, and is fatal and has limited treatment options. Characteristically IPF patients display large lymphocyte aggregates composed of CD3 T cells and CD20 B cells within the lung tissue that are located near sites of active fibrosis. In addition, IPF patients can have autoantibodies to a range of host antigens, suggesting a breakdown in immunological tolerance. In this review, we examine the role of T and B cells in IPF pathogenesis and discuss how loss of self-tolerance to lung-specific proteins could exacerbate disease progression in IPF. We discuss what these results mean in terms of future prospects for immunotherapy of IPF.

Citing Articles

Impact of soluble epoxide hydrolase inhibition on silica-induced pulmonary fibrosis, ectopic lymphoid neogenesis, and autoantibody production in lupus-prone mice.

McDonald O, Wagner J, Lewandowski R, Heine L, Estrada V, Pourmand E Inhal Toxicol. 2024; 36(7-8):442-460.

PMID: 39418113 PMC: 11606782. DOI: 10.1080/08958378.2024.2413373.

Exploring the Interplay between Cellular Senescence, Immunity, and Fibrosing Interstitial Lung Diseases: Challenges and Opportunities.

Hernandez-Gonzalez F, Pietrocola F, Cameli P, Bargagli E, Prieto-Gonzalez S, Cruz T Int J Mol Sci. 2024; 25(14).

PMID: 39062798 PMC: 11276754. DOI: 10.3390/ijms25147554.

Lung immune signatures define two groups of end-stage IPF patients.

Cruz T, Mendoza N, Casas-Recasens S, Noell G, Hernandez-Gonzalez F, Frino-Garcia A Respir Res. 2023; 24(1):236.

PMID: 37770891 PMC: 10540496. DOI: 10.1186/s12931-023-02546-8.

Comparison of COVID-19 Vaccine-Associated Myocarditis and Viral Myocarditis Pathology.

Hamedi K, Loftus G, Traylor L, Goodwin R, Arce S Vaccines (Basel). 2023; 11(2).

PMID: 36851240 PMC: 9967770. DOI: 10.3390/vaccines11020362.

[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial.

Adams H, Garde E, Vugts D, Grutters J, Oyen W, Keijsers R Eur J Nucl Med Mol Imaging. 2023; 50(7):1929-1939.

PMID: 36826476 PMC: 10199842. DOI: 10.1007/s00259-023-06143-1.

References

Xue J, Kass D, Bon J, Vuga L, Tan J, Csizmadia E . Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol. 2013; 191(5):2089-95. PMC: 3804013. DOI: 10.4049/jimmunol.1203476. View

Zhou L, Lopes J, Chong M, Ivanov I, Min R, Victora G . TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008; 453(7192):236-40. PMC: 2597437. DOI: 10.1038/nature06878. View

Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray M, Fagart J . Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 183(6):759-66. DOI: 10.1164/rccm.201001-0076OC. View

Reynolds H, Fulmer J, Kazmierowski J, Roberts W, Frank M, Crystal R . Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest. 1977; 59(1):165-75. PMC: 333344. DOI: 10.1172/JCI108615. View

Richeldi L, Collard H, du Bois R, Jenkins G, Kolb M, Maher T . Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. Eur Respir J. 2013; 42(1):230-8. DOI: 10.1183/09031936.00038613. View

Richards T, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D . Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 185(1):67-76. PMC: 3262037. DOI: 10.1164/rccm.201101-0058OC. View

Meraouna A, Cizeron-Clairac G, Le Panse R, Bismuth J, Truffault F, Tallaksen C . The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood. 2006; 108(2):432-40. PMC: 1847364. DOI: 10.1182/blood-2005-06-2383. View

Daniil Z, Kitsanta P, Kapotsis G, Mathioudaki M, Kollintza A, Karatza M . CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis. Respir Res. 2005; 6:81. PMC: 1199622. DOI: 10.1186/1465-9921-6-81. View

Feghali-Bostwick C, Tsai C, Valentine V, Kantrow S, Stoner M, Pilewski J . Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol. 2007; 179(4):2592-9. DOI: 10.4049/jimmunol.179.4.2592. View

10.

Parra E, Kairalla R, de Carvalho C, Eher E, Capelozzi V . Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration. 2006; 74(2):159-69. DOI: 10.1159/000097133. View

11.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

12.

Okazaki T, Nakao A, Nakano H, Takahashi F, Takahashi K, Shimozato O . Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J Immunol. 2001; 167(4):1977-81. DOI: 10.4049/jimmunol.167.4.1977. View

13.

Cancro M, DCruz D, Khamashta M . The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009; 119(5):1066-73. PMC: 2673851. DOI: 10.1172/JCI38010. View

14.

Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T . Circulating cytokeratin 8:anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration. 2000; 67(4):397-401. DOI: 10.1159/000029537. View

15.

Vittal R, Mickler E, Fisher A, Zhang C, Rothhaar K, Gu H . Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis. PLoS One. 2013; 8(10):e76451. PMC: 3804565. DOI: 10.1371/journal.pone.0076451. View

16.

Maher T, Evans I, Bottoms S, Mercer P, Thorley A, Nicholson A . Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 182(1):73-82. PMC: 2902759. DOI: 10.1164/rccm.200905-0674OC. View

17.

Campbell D, Poulter L, Janossy G, du Bois R . Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax. 1985; 40(6):405-11. PMC: 460088. DOI: 10.1136/thx.40.6.405. View

18.

Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D . Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012; 21(126):355-61. PMC: 9487229. DOI: 10.1183/09059180.00002512. View

19.

Marchal-Somme J, Uzunhan Y, Marchand-Adam S, Valeyre D, Soumelis V, Crestani B . Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol. 2006; 176(10):5735-9. DOI: 10.4049/jimmunol.176.10.5735. View

20.

Burzyn D, Benoist C, Mathis D . Regulatory T cells in nonlymphoid tissues. Nat Immunol. 2013; 14(10):1007-13. PMC: 4708287. DOI: 10.1038/ni.2683. View